Klin Farmakol Farm. 2017;31(1):11-14 | DOI: 10.36290/far.2017.003

New hepatitis C therapy

Petr Husa, Petr Husa ml., Matúš Mihalčin
Klinika infekčních chorob LF MU a FN Brno

Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarily
favorable safety profile. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other
DAA (ledipasvir, daclatasvir) or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir ± dasabuvir. Fixed
combinations of elbasvir and grazoprevir, and sofosbuvir + velpatasvir are already available in many countries of the world. Very probable
new fixed combinations sofosbuvir + velpatasvir + voxilaprevir, and glecaprevir + pibrentasvir will be approved in the year 2017.

Keywords: chronic hepatitis C, sofosbuvir, ledipasvir, daclatasvir, velpatasvir, paritaprevir, ombitasvir, dasabuvir, elbasvir, grazoprevir,
voxilaprevir, glecaprevir, pibrentasvir.

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P, Husa P, Mihalčin M. New hepatitis C therapy. Klin Farmakol Farm. 2017;31(1):11-14. doi: 10.36290/far.2017.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. Summary. Dostupné na: www.easl.eu/medias/cpg/HCV2016/Summary.pdf. Staženo 30.9.2016.
    2. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné na www.hcvguidelines.org. Staženo 15. 8. 2016.
    3. Pawlotsky JM. Hepatitis C virus resistance to Direct-Acting Antiviral drugs in interferon-free regimens. Gastroenterology 2016; 151: 70-86. Go to original source... Go to PubMed...
    4. University of Liverpool. Drug interactions charts. Dostupné na www.hep-druginteractions.com.
    5. HARVONI. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf. Staženo 15.8.2016.
    6. SOVALDI. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf. Staženo 15.8.2016.
    7. EPCLUSA. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf. Staženo 15.8.2016.
    8. VIEKIRAX. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf. Staženo 15.8.2016.
    9. EXVIERA. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf. Staženo 15.8.2016.
    10. UrbáneK P. Exviera, Viekirax. Gastroent Hepatol, 2015; 69: 75-80. Go to original source...
    11. ZEPATIER. Souhrn údajů o přípravku. Dostupné na: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/004126/WC500211235.pdf. Staženo 15.8.2016.
    12. Bourliére M, Gordon SC, Ramji A, et al. Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1-6 infection: The phase 3 POLARIS-1 study. Hepatology 2016; 63(Suppl.1): 102A-103A.
    13. Jacobsson IM, Asselah T, Nahass R, et al. A randomized phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir for 8 weeks compared to sofosbuvir/velpatasvir for 12 weeks in DAA-na?ve genotype 1-6 HCV infected patients: The POLARIS-2 study. 67th Annual meeting of AASLD, Boston, 11.-15. 11. 2016.
    14. Foster GR, Thompson A, Ruane PJ, et al. A randomized, phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir for 8 weeks and sofosbuvir/velpatasvir for 12 weeks for patients with genotype 3 HCV infection and cirrhosis: The POLARIS-3 study. Hepatology 2016; 63(Suppl.1): 135A-136A.
    15. Zeuzem S, Flamm SL, Tong M, et al. A randomized, controlled, phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir for 8 weeks and sofosbuvir/velpatasvir for 12 weeks in Direct-Acting Antiviral-experienced patients with genotype 1-6 HCV infection: The POLARIS-4 study. Hepatology 2016; 63(Suppl.1): 56A.
    16. Zeuzem S, Feld JJ, Wang S, et al. ENDURANCE-1: Efficacy and safety of 8-versus 12-week treatment with ABT-493/ABT-530 in patient with chronic HCV genotype 1 infection. Hepatology 2016; 63(Suppl.1): 132A-133A.
    17. Kowdley KV, Colombo M, Zadeikis N, et al. ENDURANCE-2: Safety and efficacy of ABT-493/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study. Hepatology 2016; 63(Suppl.1): 39A.
    18. Assela HT, Hezode C, Zadeikis N, et al. ENDURANCE-4: Efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Hepatology 2016; 63(Suppl.1): 63A.
    19. Wyles DL, Poordad F, Wang S, et al. SURVEYOR-II, Part 3: Efficacy and safety of ABT-493/ABT-530 in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. Hepatology 2016; 63(Suppl.1): 62A-63A.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.